Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14185644 | 1.00 | HIF1A (0.45) | HIF1ACES2CES1TP53SMN1; SMN2 | |
| Isoxazole SCHEMBL4373885 | 0.88 | HIF1A (0.37) | HIF1ACES2CES1TP53SMN1; SMN2 | |
| SCHEMBL11208465 | 0.81 | HIF1A (0.44) | HIF1ATP53SMN1; SMN2 | |
| SCHEMBL11202946 | 0.81 | HIF1A (0.46) | HIF1ATP53SMN1; SMN2CA12CA1 | |
| SCHEMBL5294295 | 0.80 | HIF1A (0.45) | HIF1ATP53SMN1; SMN2CA12CA1 | |
| SCHEMBL9689288 | 0.78 | FAAH (0.46) | HIF1ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL11211934 | 0.78 | HIF1A (0.43) | HIF1ATP53SMN1; SMN2CA12CA1 | |
| SCHEMBL753859 | 0.76 | HIF1A (0.42) | HIF1ATP53SMN1; SMN2CA12CA1 | |
| SCHEMBL4983840 | 0.76 | HIF1A (0.42) | HIF1ATP53SMN1; SMN2CA12CA1 | |
| SCHEMBL8663680 | 0.75 | ESR1 (0.42) | HIF1ASMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3852790-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113164571-A | Inhibition of ubiquitin-specific peptidase 9X | 福马治疗股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020061261-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20170298080-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-10-19 | — | — | US | disclosed |
| US-20170298080-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-10-19 | — | — | US | disclosed |
| EP-3192792-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Vigonvita Life Sciences Co., Ltd. (CN) | 2017-07-19 | — | — | EP | disclosed |
| EP-2422780-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2422781-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2422781-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2006-11-16 | — | — | US | disclosed |
| US-20060135582-A1 | Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof | DIPHARMA S.P.A. (IT) | 2006-06-22 | — | — | US | disclosed |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1581508-A1 | A PROCESS FOR THE PREPARATION OF BENZO D ISOXAZOL-3-YL- METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF | Dipharma S.p.A. (IT) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005044808-A1 | A PROCESS FOR THE MANUFACTURE OF ZONISAMIDE | WOCKHARDT LIMITED (IN) | 2005-05-19 | — | — | WO | disclosed |
| WO-2004063173-A1 | A PROCESS FOR THE PREPARATION OF BENZO[D]ISOXAZOL-3-YL-METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF | DIPHARMA S.P.A. (IT) | 2004-07-29 | — | — | WO | disclosed |
| US-4957931-A | ANTICONVULSANTS, TREATMENT OF EPILEPSY | CIBA-GEIGY CORPORATION (US) | 1990-09-18 | — | — | US | disclosed |
| US-4859691-A | Certain 1,2-benzisoxazole derivatives | CIBA-GEIGY CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | HIF1A 2942/4885CES2 2870/4885CES1 671/4885 |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | HIF1A 3659/4885CES2 41/4885CES1 162/4885 |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | HIF1A 3659/4885CES2 41/4885CES1 162/4885 |
| US-20170298080-A1 | AMINOSULFONYL COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | NOTUM, ALDH7A1, HADHB | HIF1A 4097/4885CES2 607/4885CES1 116/4885 |
| US-20060135582-A1 | Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof | GABRD, GABRA5, GABRA6 | HIF1A 4044/4885CES2 2469/4885CES1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.